| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Cloricromen targets platelet aggregation and thrombus formation. It inhibits the release of thromboxane B2 and β-thromboglobulin, which are key mediators of platelet activation and aggregation. It also enhances the production of prostacyclin by vascular endothelium. These effects contribute to its antithrombotic activity.
|
|---|---|
| ln Vitro |
In vitro, cloricromen inhibits platelet aggregation in human platelets. It inhibits thromboxane B2 release and β-thromboglobulin. It is used in research on thrombosis and platelet function. Its specific in vitro potency (IC50) against platelet aggregation is an area of research.
|
| ln Vivo |
In vivo, cloricromen is an orally active platelet aggregation inhibitor. It inhibits thrombus formation. It is a coronary vasodilator and antithrombotic agent. It is used in research on cardiovascular diseases and thrombosis.
|
| Enzyme Assay |
Cell-free assays for cloricromen measure inhibition of thromboxane B2 production. Platelets or purified enzymes (e.g., thromboxane synthase) are incubated with arachidonic acid and varying concentrations of cloricromen (0.1-100 µM). Thromboxane B2 levels are measured by ELISA. Platelet aggregation assays are performed using platelet-rich plasma and light transmission aggregometry.
|
| Cell Assay |
In vitro cellular assays for cloricromen use platelets or endothelial cells. Platelets are treated with cloricromen at concentrations of 0.1-100 µM for 5-10 minutes. Platelet aggregation is induced by ADP, collagen, or thrombin and monitored by light transmission aggregometry. Thromboxane B2 and β-thromboglobulin levels are measured by ELISA. Prostacyclin production by endothelial cells is measured by 6-keto-PGF1α ELISA.
|
| Animal Protocol |
In vivo animal experiments for cloricromen use rodent models of thrombosis (e.g., ferric chloride-induced arterial thrombosis). Cloricromen is administered orally at doses of 1-50 mg/kg. Endpoints include occlusion time, thrombus weight, and bleeding time. Platelet aggregation ex vivo is measured to confirm target engagement. Thromboxane B2 levels in plasma are measured by ELISA.
|
| References | |
| Additional Infomation |
Cloricromen is a type of coumarin compound.
|
| Molecular Formula |
C20H26CLNO5
|
|---|---|
| Molecular Weight |
395.87714
|
| Exact Mass |
395.15
|
| CAS # |
68206-94-0
|
| Related CAS # |
Cloricromen hydrochloride;74697-28-2
|
| PubChem CID |
68876
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.189g/cm3
|
| Boiling Point |
514.1ºC at 760mmHg
|
| Melting Point |
221-222.3ºC
|
| Flash Point |
264.7ºC
|
| Index of Refraction |
1.532
|
| LogP |
3.581
|
| tPSA |
68.98
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
27
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOC(COC1C=CC2C(=C(C(OC=2C=1Cl)=O)CCN(CC)CC)C)=O
|
| InChi Key |
GYNNRVJJLAVVTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H26ClNO5/c1-5-22(6-2)11-10-15-13(4)14-8-9-16(26-12-17(23)25-7-3)18(21)19(14)27-20(15)24/h8-9H,5-7,10-12H2,1-4H3
|
| Chemical Name |
ethyl 2-[8-chloro-3-[2-(diethylamino)ethyl]-4-methyl-2-oxochromen-7-yl]oxyacetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5260 mL | 12.6301 mL | 25.2602 mL | |
| 5 mM | 0.5052 mL | 2.5260 mL | 5.0520 mL | |
| 10 mM | 0.2526 mL | 1.2630 mL | 2.5260 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.